Fluconazole Prices in the Global Market
North America
In the fourth quarter of 2022, the Fluconazole Prices in the North American region showcased an irregular trajectory. It was projected at the start of Q4 2022 that prices would rise in the second month of the quarter due to increasing end-user sector demand and other logistical challenges. The implementation of zero covid rules hampered trading activity and halted shipments, which benefited the Fluconazole market. The market remained competitive despite higher manufacturing costs brought on by rising energy prices. However, later in December, as a result of domestic retailers having an adequate supply on hand, fluconazole API prices did decrease. Because of the policies being loosened and the weak downstream demand, the market remained depressed. By the end of Q3 2022, prices were recorded to drop, with values accessed at USD 159020/MT with an average quarterly inclination of 0.99%.
Asia
Fluconazole sales in the Asia Pacific Region had an erratic fourth-quarter trajectory in 2022. It was indicated at the beginning of Q4 2022 that due to rising end-user sector demand and various logistical issues, prices would increase during the second month of the quarter. The adoption of zero covid regulations disrupted shipments and hindered trading activity, which had a favorable impact on the Fluconazole market. Due to increased manufacturing costs driven by rising energy prices, the market remained competitive. Later in December, though, fluconazole API prices did drop because domestic stores had enough inventory on hand. The market remained poor as a result of the relaxing of policies as well as the lackluster downstream demand. Towards the end of Q4, the prices of Salicylic acid were recorded at USD 153200/ton FOB Shanghai (China), with an average quarterly inclination of 0.54%.
Europe
In the third quarter of 2022, Prices of Fluconazole API market sentiments in Europe showcased fluctuating behaviors. At the start of Q4 2022 that prices rose till the second month of the quarter as a result of increasing end-user sector demand and other logistical challenges. The implementation of zero covid rules hampered trading activity and halted shipments, which benefited the fluconazole market in the European region. The market remained competitive despite higher manufacturing costs brought on by rising energy prices. However, later in December, because of domestic retailers having an adequate supply on hand, fluconazole API prices did decrease. Also, policies being loosened and the weak downstream demand, the market remained depressed in December. Toward the end of Q4, the values accessed at USD 162020/MT with an average quarterly inclination of 0.67%.
ChemAnalyst addresses the key problematic areas and risks associated with chemical and petrochemical business globally and enables the decision-maker to make smart choices. It identifies and analyses factors such as geopolitical risks, environmental risks, raw material availability, supply chain functionality, disruption in technology and so on. It targets market volatility and ensures clients navigate through challenges and pitfalls in an efficient and agile manner. Timeliness and accuracy of data has been the core competency of ChemAnalyst, benefitting domestic as well as global industry in tuning in to the real-time data points to execute multi-billion-dollar projects globally.
コメント